<p>泰格医药 (03347.HK) -2.000 (-5.260%) 空头头寸 $12.33M; 比率 8.718% 披露其联合创始人及控股股东叶小平和曹晓春因未能及时披露股权变动而收到中国证券监督管理委员会的正式立案通知，因其持股比例在 2014 年 12 月至 2026 年 5 月之间下降超过 10 个百分点，花旗在一份研究报告中表示。</p>
<p>花旗认为这构成合规程序违规，最可能的解决方案是警告和罚款，待处罚明确。该券商认为此事件对公司的基本面没有影响，并将任何股价疲软视为增强的买入机会。</p>
<p>该券商给予泰格医药咨询 (300347.SZ) -2.440 (-4.735%) A 股目标价为人民币 67，并维持买入评级。</p>
<p>(港股报价延迟至少 15 分钟。空头数据截至 2026-05-13 12:25。)(A 股报价延迟至少 15 分钟。)</p>

泰格医药

华夏中证生物科技主题ETF

招商中证生物科技主题ETF

易方达中证生物科技主题ETF

<p>花旗集团报告称，由于其联合创始人未能披露股权变动，泰格医药的股票下跌了 5.26%。尽管如此，花旗认为公司的基本面依然强劲，并将股价下跌视为买入机会。该券商为泰格医药设定了 67 元人民币的目标价，并维持 “买入” 评级</p>

<p>TIGERMED (03347.HK) -2.000 (-5.260%)  Short selling $12.33M; Ratio 8.718%  disclosed that its co-founders and controlling shareholders, Ye Xiaoping and Cao Xiaochun, received formal case filing notices from the China Securities Regulatory Commission for failing to promptly disclose equity changes after their shareholding ratios fell by more than 10 ppts between December 2014 and May 2026, Citi said in a research report.</p>
<div class="lb-trans"><p>泰格医药 (03347.HK) -2.000 (-5.260%) 空头头寸 $12.33M; 比率 8.718% 披露其联合创始人及控股股东叶小平和曹晓春因未能及时披露股权变动而收到中国证券监督管理委员会的正式立案通知，因其持股比例在 2014 年 12 月至 2026 年 5 月之间下降超过 10 个百分点，花旗在一份研究报告中表示。</p>
</div><p>Citi believed this constitutes a compliance procedural violation, with the most likely resolution being a warning and fine, pending clarification of penalties. The broker believed the incident has no impact on the company's fundamentals and viewed any share price weakness as an enhanced buying opportunity.</p>
<div class="lb-trans"><p>花旗认为这构成合规程序违规，最可能的解决方案是警告和罚款，待处罚明确。该券商认为此事件对公司的基本面没有影响，并将任何股价疲软视为增强的买入机会。</p>
</div><p>The broker assigned TIGERMED CONSULTING (300347.SZ) -2.440 (-4.735%)  an A-share TP of RMB67 and maintained a Buy rating.</p>
<div class="lb-trans"><p>该券商给予泰格医药咨询 (300347.SZ) -2.440 (-4.735%) A 股目标价为人民币 67，并维持买入评级。</p>
</div><p>(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-13 12:25.) (A Shares quote is delayed for at least 15 mins.)</p>
<div class="lb-trans"><p>(港股报价延迟至少 15 分钟。空头数据截至 2026-05-13 12:25。)(A 股报价延迟至少 15 分钟。)</p>
</div>

花旗银行认为泰格医药咨询的基本面未受影响，股价疲软被视为入场机会